Key takeaways
- The "Process is the Product": For cell and gene therapies, manufacturing is scientifically intertwined with clinical efficacy; outsourcing risks diluting the tribal knowledge required to troubleshoot complex biological deviations.
- The CAPEX trap: Building in-house offers total control but requires massive upfront capital and, crucially, a specialized workforce that is currently in shorter supply than the bioreactors themselves.
- The "Hybrid" hegemony: The industry is converging on a hybrid model—keeping early-stage process development and "secret sauce" vector design in-house while outsourcing commoditized scale-up and fill-finish operations.
- Tech transfer friction: Moving a novel modality from an innovative biotech lab to a standardized CDMO suite often reveals that the process isn't as robust as thought, leading to costly "re-development" delays.
In the small molecule era, manufacturing was a commodity. You sent a recipe to a factory, and identical white pills came out the other side. In the era of outsourcing manufacturing for emerging modalities in therapeutics like CAR-T and gene editing, manufacturing is a science. The "recipe" is a living biological process that is sensitive to minor fluctuations in temperature, shear stress, and raw material provenance.
For biotech CEOs, the "build vs. buy" decision has morphed from a financial calculation into an existential one. Building internal capacity (In-House) secures intellectual property and agility but burns precious cash. Partnering with a Contract Development and Manufacturing Organization (Outsourcing) saves capital but surrenders control over the most critical variable in the drug's success: the process itself.
The case for building: When outsourcing manufacturing for therapeutics risks control
For autologous cell therapies, where every batch is a patient, the supply chain is the therapy. Companies like Kite Pharma (now Gilead) famously chose to build massive internal manufacturing networks to guarantee turnaround times for Yescarta.
The primary argument for in-house manufacturing is agility. When a process deviation occurs—and in biology, it always does—an internal team can pivot immediately. In an outsourced model, you are one of many clients in a queue, waiting for a deviation report. Furthermore, for novel modalities where the "process is the product," keeping manufacturing in-house prevents critical know-how from leaking or being diluted. If your competitive advantage is a proprietary transduction method, teaching it to a third party is a strategic risk [1].
The case for buying: The speed advantage of outsourcing manufacturing for therapeutics
Conversely, the capital expenditure (CAPEX) required to build a GMP facility is staggering—often exceeding $100 million before a single patient is dosed. For pre-revenue biotechs, outsourcing manufacturing for therapeutics is often the only viable path to the clinic.
CDMOs offer "plug-and-play" infrastructure and, perhaps more importantly, regulatory experience. A top-tier CDMO has likely navigated FDA audits for similar modalities dozens of times. They offer a "regulatory umbrella" that can shield a young biotech from compliance stumbling blocks. Additionally, the post-COVID market correction has led to some capacity opening up in viral vector manufacturing, making outsourcing more accessible than it was during the 2021 crunch [2].
The hybrid compromise: The best of both worlds?
The binary choice between "build" or "buy" is fading. The emerging standard is a hybrid model. In this scenario, a company retains internal capabilities for Process Development (PD) and early-phase clinical supply (Phase 1/2), ensuring they fully understand and "own" their science.
Once the process is locked and the therapy moves to large-scale Phase 3 or commercial distribution, the optimized process is transferred to a CDMO for scale-up. This allows the innovator to control the science during the critical de-risking phase while leveraging the CDMO's muscle for volume production. However, this model relies entirely on the success of "tech transfer"—the perilous handoff of data and protocols between organizations, which remains a primary source of failure in the industry [3].
Comparing in-house and outsourced manufacturing models
Feature | In-House Manufacturing | Outsourced (CDMO) |
|---|---|---|
Upfront Cost (CAPEX) | Very High ($50M - $100M+) | Low (Service fees) |
Operational Control | Total (Real-time pivoting) | Limited (Slot-based) |
IP Protection | High (Internal "walled garden") | Moderate (Shared environments) |
Speed to Clinic | Slow (Build & Validate time) | Fast (Existing infrastructure) |
Talent Requirement | High (Must hire specialized staff) | Low (Access to CDMO staff) |
The hidden bottleneck in outsourcing manufacturing for therapeutics: Talent, not tanks
A critical, often overlooked factor in the outsourcing manufacturing for therapeutics debate is human capital. You can buy a bioreactor, but you cannot easily buy a team with ten years of experience in purifying adeno-associated virus (AAV).
The industry is facing a severe shortage of bioprocess engineers. CDMOs, by virtue of their scale, often hoover up this talent, creating centers of excellence that individual biotechs struggle to replicate. For many companies, outsourcing is not a choice about steel tanks, but a choice about accessing the brains capable of running them [4].
Conclusion: Strategy dictates structure
There is no single right answer. The decision to outsource or build must align with the company's funding runway, the complexity of the modality, and the stage of development. For a standard monoclonal antibody, outsourcing is a safe bet. For a complex, patient-specific gene edit, internal control might be worth the premium. Ultimately, the goal is the same: to ensure that when the science succeeds in the lab, it doesn't fail on the factory floor.
References
Miyoura, S., et al. (2024). The Ins And Outs Of In-House Manufacturing: Building A Cell & Gene Production Facility. Cell & Gene.
AGC Biologics. (2025). Trends Shaping the Future of Cell and Gene Therapy Manufacturing. Biopharma Blog.
Evotec. (2025). A Guide to Cell Therapy Technology Transfer. Industry Whitepaper.
BDO USA. (2025). Mastering the Build vs. Buy Decision in Life Sciences Manufacturing. Insights.
